# Enhancing wound healing with synergistic dual-drug electrospun roflumilast and L-arginine loaded PLA/PVA nanofibers through fabrication, optimization, and in vivo assessment

**Authors:** Samar A. Salim, Abdullah M. M. Elbadry, Esraa B. Abdelazim, Tasneem Abed, Marwa Mosaad Shakweer, Noura G. Eissa, Elbadawy A. Kamoun, Mahmoud Elsabahy

PMC · DOI: 10.1038/s41598-026-38086-6 · Scientific Reports · 2026-02-20

## TL;DR

Researchers developed a new wound healing scaffold using two drugs in nanofibers, which showed excellent healing in animal tests.

## Contribution

A novel dual-drug electrospun scaffold combining roflumilast and L-arginine for enhanced wound healing is introduced.

## Key findings

- Dual-drug loaded nanofibers achieved ~99.8% wound healing in 14 days in rats.
- Histology showed improved re-epithelialization and no residual granulation tissue.
- Maximum initial swelling of 610% was observed in the dual-drug loaded fibers.

## Abstract

Current trends in improved wound management emphasize the development of dual-drug-loaded electrospun nanofibrous scaffolds. Herein, electrospun dual-drug loaded PLA/PVA nanofibrous scaffolds, incorporating roflumilast, a selective phosphodiesterase-4 inhibitor with anti-inflammatory activity, and L-arginine, a precursor to nitric oxide with stimulating activity towards wound healing and tissue regeneration, were developed. A dual-spinneret electrospinning process enabled the co-loading of drugs in PLA and PVA phases. Scaffolds were characterized by SEM, FTIR, and XRD, showing consistent fiber morphology, and amorphous drug formation. FTIR analysis was performed to confirm drug–polymer compatibility and successful incorporation of roflumilast and L-arginine within the PLA/PVA nanofibrous matrix. Swelling ratio analysis indicated controlled hydration behavior regarding polymer–drug composition, and dual-drug-loaded fibers exhibited maximum initial swelling (610%) and stabilization at ~ 240%. In vivo rat excision wound healing model showed that the dual-drug loaded nanofibers demonstrated enhanced wound healing with ~ 99.8% healing on day 14, which was significantly better, compared to nanofibers incorporating a single drug and control groups. Moreover, histological studies revealed the absence of residual granulation tissue and enhanced re-epithelialization in the dual-drug treated group. These results indicate that roflumilast and L-arginine co-loaded PLA/PVA nanofibers exhibit wound-healing and regenerative properties, offering a promising therapeutic platform for enhanced wound repair.

## Linked entities

- **Chemicals:** roflumilast (PubChem CID 449193), L-arginine (PubChem CID 232), PLA (PubChem CID 1018), PVA (PubChem CID 11199)
- **Species:** Rattus norvegicus (taxon 10116)

## Full-text entities

- **Genes:** CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, GH1 (growth hormone 1) [NCBI Gene 2688] {aka GH, GH-N, GHB5, GHN, IGHD1A, IGHD1B}, PDE4A (phosphodiesterase 4A) [NCBI Gene 5141] {aka DPDE2, PDE4, PDE46}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** psoriasis (MESH:D011565), chronic obstructive pulmonary disease (MESH:D029424), Swelling (MESH:D004487), chronic bronchitis (MESH:D029481), fibrosis (MESH:D005355), inflammatory (MESH:D007249), Wounds (MESH:D014947), dermal injuries (MESH:D016136), infection (MESH:D007239)
- **Chemicals:** hyaluronic acid (MESH:D006820), cAMP (MESH:D000242), NO (MESH:D009569), glutamate (MESH:D018698), Cu (MESH:D003300), F2 (MESH:D005461), water (MESH:D014867), Roflumilast (MESH:C424423), amide (MESH:D000577), Polymer (MESH:D011108), PVA (MESH:C063253), ester (MESH:D004952), xylazine (MESH:D014991), oxygen (MESH:D010100), chitosan (MESH:D048271), acid (MESH:D000143), vitamin D (MESH:D014807), proline (MESH:D011392), guanidine (MESH:D019791), formalin (MESH:D005557), hydrogen (MESH:D006859), Eosin (MESH:D004801), acetate (MESH:D000085), PLA (MESH:C033616), chloroform (MESH:D002725), polyamines (MESH:D011073), L-Arginine (MESH:D001120), creatine (MESH:D003401), amine (MESH:D000588), amino acid (MESH:D000596), urea (MESH:D014508), PVA (MESH:D011142), hematoxylin (MESH:D006416), hydroxyproline (MESH:D006909), ornithine (MESH:D009952), aluminum (MESH:D000535), F1 (-)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Cell lines:** H&amp;E — Homo sapiens (Human), Transformed cell line (CVCL_ZD53), BUC-IACUC-241020-115 — Homo sapiens (Human), Childhood T acute lymphoblastic leukemia, Cancer cell line (CVCL_G691)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12929595/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12929595/full.md

## References

11 references — full list in the complete paper: https://tomesphere.com/paper/PMC12929595/full.md

---
Source: https://tomesphere.com/paper/PMC12929595